Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELINEST vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy in women who elect to use oral contraceptives,Treatment of moderate acne vulgaris in women at least 14 years old who have no known contraindications and have achieved menarche,Treatment of premenstrual dysphoric disorder (PMDD) in women of reproductive age who choose to use an oral contraceptive
Prevention of pregnancy (FDA-approved)
0.5 mg orally once daily.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol is metabolized via CYP3A4 and undergoes conjugation; drospirenone is metabolized primarily via CYP3A4 to inactive metabolites.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
~98-99% bound, primarily to sex hormone-binding globulin (SHBG) and albumin, with ~45% bound to SHBG and remainder to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Apparent Vd for estradiol is ~0.6-0.7 L/kg, reflecting distribution into total body water and some tissue binding (e.g., fat and reproductive tissues).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: ~5% due to extensive first-pass metabolism, but this is sufficient for therapeutic effect with the ester prodrug enhancing absorption.
Oral: ~70% due to first-pass metabolism.
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: 0.25 mg once daily. GFR <15 m L/min: Not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: No adjustment. Child-Pugh B: 0.25 mg once daily. Child-Pugh C: Not recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Safety and efficacy not established in pediatric patients.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
No specific dose adjustment required; monitor renal function due to age-related decline.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Risk of thromboembolic disorders including stroke, myocardial infarction, and venous thromboembolism,Should not be used in women with hypertension, diabetes with vascular disease, or hyperlipidemias,May increase risk of gallbladder disease, hepatic neoplasia, and worsening of hereditary angioedema,May cause fluid retention, hyperkalemia in patients with renal impairment or on potassium-sparing drugs,Discontinue if jaundice, visual disturbances, or migraine with focal symptoms occur,May reduce folate levels; consider folate supplementation
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Benign or malignant liver tumor or active liver disease,Renal impairment (creatinine clearance <30 m L/min),Adrenal insufficiency,Hypersensitivity to any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice; may increase ethinyl estradiol exposure. Avoid potassium-rich foods in large amounts (e.g., bananas, oranges, spinach) if using potassium-sparing diuretics or ACE inhibitors. High-fat meals may increase ethinyl estradiol absorption. St. John's Wort reduces efficacy of hormonal contraceptives.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Pregnancy Category X. Contraindicated in pregnancy due to documented teratogenicity. First trimester exposure associated with cardiovascular and neural tube defects; second and third trimester exposure linked to fetal hypothalamic-pituitary-ovarian axis disruption.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in human milk; M/P ratio 0.6:1.0. Potential for serious adverse reactions in nursing infants; contraindicated during breastfeeding.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustment possible; contraindicated. If exposure occurs, discontinue immediately and refer to teratology specialist.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
ELINEST contains drospirenone and ethinyl estradiol. Drospirenone has antimineralocorticoid activity, so monitor potassium in patients with renal impairment or on potassium-sparing diuretics, NSAIDs, or ACE inhibitors. Contraindicated with adrenal insufficiency. Increased risk of venous thromboembolism (VTE) compared to other COCs; avoid in migraine with aura, hypertension >160/100 mm Hg, or age >35 and smoking ≥15 cigarettes/day. Use with caution in patients with liver disease or active gallbladder disease. If breakthrough bleeding persists beyond 3 cycles, consider alternate causes. For missed pills: if one pill missed >12 hours, take as soon as remembered; if 2+ pills missed, consider back-up contraception.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time; do not skip doses even if spotting occurs.,If you miss a pill by more than 12 hours, take it as soon as remembered and use backup contraception for 7 days.,Smoking while on ELINEST increases risk of serious cardiovascular events; avoid smoking, especially if over age 35.,Report symptoms of blood clots: sudden leg swelling/pain, chest pain, shortness of breath, or vision changes.,ELINEST may increase potassium levels; avoid potassium supplements and salt substitutes containing potassium.,Take with food to reduce nausea; avoid grapefruit juice as it may alter hormone levels.,Protection against pregnancy is not immediate; use additional contraception for the first 7 days if starting for the first time.,Stop ELINEST 4 weeks before major surgery or prolonged immobilization to reduce clot risk.,Regular gynecologic exams and blood pressure monitoring are recommended.,ELINEST does not protect against HIV or other sexually transmitted infections.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELINEST vs AFIRMELLE, answered by our medical review team.
ELINEST is a Oral Contraceptive that works by Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELINEST and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELINEST is: 0.5 mg orally once daily.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELINEST and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELINEST is classified as Category C. Pregnancy Category X. Contraindicated in pregnancy due to documented teratogenicity. First trimester exposure associated with cardiovascular and neural tube defects; second and thi. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.